Technology & Science
Jan. 21, 2011
Drug Faces Contract Dispute
Specialty drug developer Depomed Inc. will go up against a pharmaceutical giant in mediation over a contract worth hundreds of millions of dollars.
Daily Journal Staff Writer
Specialty drug developer Depomed Inc. will go up against a pharmaceutical giant in mediation over a disputed contract worth hundreds of millions of dollars.
Carl A. Pelzel, president and chief executive officer of Menlo Park-based Depomed, said the company was "perplexed" when Abbott Laboratories did an about-face recently and said that it is not obligated to launch and commercialize Depome...
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In